Treatment of nausea and vomiting in pregnancy with Sharbat Imli

A Randomized Comparative Study of Sharbat Tamarhindi Versus Doxylamine Succinate in Emesis Gravidarum (Qay-al-haml) - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072939

Enrollment

Registered

2024-08-23

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O210- Mild hyperemesis gravidarum

Interventions

Intervention1: Sharbat tamarhindi: Form Sharbat syrup Mode of administration orally Dosage 20 ml BD before food for 4 weeks Control Intervention1: doxylamine succinate: Form Tablet Dosage 10 mg bd Be

Eligibility

Inclusion criteria

Inclusion criteria: 1.Primigravida and Multigravida between the age of 18 to 35 years. 2.Gestational age of 6 to 14 week. 3.Mild to moderate NVP (3 to 12) score on the PUQE 24 scale. 4.No intake of anti-nauseant drug within at least 24 hours before visit.

Exclusion criteria

Exclusion criteria: 1.Patients with hyperemesis gravidarum. 2.Patients in whom emesis seen in second and third trimester. 3.Patients with twin pregnancy and vesicular mole. 4.Vomiting caused due to other disorders like peptic ulcer, renal calculi, appendicitis, gastritis, malignancies. 5.Patients with systemic diseases.

Design outcomes

Primary

Measure	Time frame
Reduction in severity of nausea and vomiting by PUQE index.Timepoint: two follow ups weekly on 5 and 6 week	—

Secondary

Measure	Time frame
Improvement of quality of life by NVPQOL questionnaire.Timepoint: two follow ups weekly on 5 and 6 week	—

Countries

India

Contacts

Public ContactDr Nikhat Kausar Inamdar

Luqman Unani Medical College Hospital and Research Center, Vijaypur, 586101

aqilquadri@yahoo.com9849090182

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026